Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate efficacy and safety information about RBX2660 for the treatment of
recurrent Clostridium difficile infection (CDI), and will compare the efficacy of one
treatment with RBX2660 versus antibiotic-treated historical controls. Enrolled subjects will
receive one treatment consisting of two doses of RBX2660 (microbiota suspension).